Study of a new drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has not responded to standard treatments or you cannot have them.
- If you have liver cancer, you may join even if you have not had previous treatment.
- If you have stomach or esophageal cancer, you must have had one line of chemo and immunotherapy that stopped working.
- If you have brain cancer, you must have had prior treatment with bevacizumab or similar drugs.
- You must have at least one tumor that can be measured and have not had it treated with local therapy recently.
- You must have adequate organ and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-4508 for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe, how the body processes it, and if it helps shrink tumors.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.